nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—peripheral nervous system—type 2 diabetes mellitus	0.0371	0.495	CbGeAlD
Fosaprepitant—TACR1—nerve—type 2 diabetes mellitus	0.0289	0.386	CbGeAlD
Fosaprepitant—TACR1—adipose tissue—type 2 diabetes mellitus	0.00893	0.119	CbGeAlD
Fosaprepitant—Aprepitant—CYP1A2—type 2 diabetes mellitus	0.00629	0.602	CrCbGaD
Fosaprepitant—Aprepitant—CYP3A4—type 2 diabetes mellitus	0.00416	0.398	CrCbGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—TRPC6—type 2 diabetes mellitus	0.00174	0.00714	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GCGR—type 2 diabetes mellitus	0.00171	0.00702	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—AGTR2—type 2 diabetes mellitus	0.00171	0.00701	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—EDNRB—type 2 diabetes mellitus	0.00165	0.0068	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—EDNRB—type 2 diabetes mellitus	0.00163	0.00671	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—HTR2C—type 2 diabetes mellitus	0.00161	0.0066	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GIPR—type 2 diabetes mellitus	0.00157	0.00646	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—EDNRA—type 2 diabetes mellitus	0.00156	0.00642	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—type 2 diabetes mellitus	0.00155	0.00638	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB3—type 2 diabetes mellitus	0.00155	0.00635	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—EDNRA—type 2 diabetes mellitus	0.00154	0.00634	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GHRL—type 2 diabetes mellitus	0.00152	0.00625	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—GHRL—type 2 diabetes mellitus	0.0015	0.00617	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—GJA1—type 2 diabetes mellitus	0.00148	0.0061	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—type 2 diabetes mellitus	0.00148	0.00608	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—AR—type 2 diabetes mellitus	0.00147	0.00605	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—MC4R—type 2 diabetes mellitus	0.00144	0.00591	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2C—type 2 diabetes mellitus	0.00144	0.0059	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—type 2 diabetes mellitus	0.0014	0.00574	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GCG—type 2 diabetes mellitus	0.00139	0.00572	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—GNB3—type 2 diabetes mellitus	0.00139	0.0057	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—PPARGC1A—type 2 diabetes mellitus	0.00139	0.0057	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GIP—type 2 diabetes mellitus	0.00138	0.00569	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—RASGRP1—type 2 diabetes mellitus	0.00137	0.00563	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—AVP—type 2 diabetes mellitus	0.00137	0.00562	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—MTNR1B—type 2 diabetes mellitus	0.00136	0.00561	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—type 2 diabetes mellitus	0.00136	0.00559	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—LEP—type 2 diabetes mellitus	0.00132	0.00544	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCKAR—type 2 diabetes mellitus	0.00131	0.00538	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—type 2 diabetes mellitus	0.00125	0.00512	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—ICAM1—type 2 diabetes mellitus	0.00124	0.00511	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—NOS2—type 2 diabetes mellitus	0.00123	0.00507	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—type 2 diabetes mellitus	0.00122	0.00503	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—GNB3—type 2 diabetes mellitus	0.0012	0.00493	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—NR3C1—type 2 diabetes mellitus	0.00119	0.00489	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—AVP—type 2 diabetes mellitus	0.00118	0.00486	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB3—type 2 diabetes mellitus	0.00118	0.00483	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—AVP—type 2 diabetes mellitus	0.00117	0.0048	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—type 2 diabetes mellitus	0.00114	0.0047	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CRHR1—type 2 diabetes mellitus	0.00114	0.00467	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—EDN1—type 2 diabetes mellitus	0.00113	0.00463	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—MTNR1A—type 2 diabetes mellitus	0.00112	0.00459	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CCL2—type 2 diabetes mellitus	0.00111	0.00457	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—EDN1—type 2 diabetes mellitus	0.00111	0.00457	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—EDNRB—type 2 diabetes mellitus	0.0011	0.0045	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—HIF1A—type 2 diabetes mellitus	0.00108	0.00446	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNB3—type 2 diabetes mellitus	0.00107	0.00441	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—HTR2C—type 2 diabetes mellitus	0.00106	0.00437	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—type 2 diabetes mellitus	0.00106	0.00435	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—type 2 diabetes mellitus	0.00106	0.00435	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—MTNR1B—type 2 diabetes mellitus	0.00104	0.00427	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—EDNRA—type 2 diabetes mellitus	0.00103	0.00425	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MTNR1A—type 2 diabetes mellitus	0.00102	0.00417	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GLP1R—type 2 diabetes mellitus	0.00101	0.00416	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—type 2 diabetes mellitus	0.00101	0.00416	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—GHRL—type 2 diabetes mellitus	0.00101	0.00414	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—type 2 diabetes mellitus	0.00101	0.00414	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CCKAR—type 2 diabetes mellitus	0.000997	0.00409	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCR5—type 2 diabetes mellitus	0.000994	0.00408	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—C3—type 2 diabetes mellitus	0.000971	0.00399	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GCGR—type 2 diabetes mellitus	0.000965	0.00397	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—AGT—type 2 diabetes mellitus	0.000935	0.00384	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—AGT—type 2 diabetes mellitus	0.000923	0.00379	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—PTGS2—type 2 diabetes mellitus	0.000907	0.00373	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—IAPP—type 2 diabetes mellitus	0.000897	0.00369	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GIPR—type 2 diabetes mellitus	0.000888	0.00365	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GRK5—type 2 diabetes mellitus	0.000888	0.00365	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GCGR—type 2 diabetes mellitus	0.000877	0.0036	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—AGTR2—type 2 diabetes mellitus	0.000871	0.00358	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CASP3—type 2 diabetes mellitus	0.000842	0.00346	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—type 2 diabetes mellitus	0.000836	0.00343	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—EDNRB—type 2 diabetes mellitus	0.000834	0.00343	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ARAP1—type 2 diabetes mellitus	0.00083	0.00341	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—MC4R—type 2 diabetes mellitus	0.000812	0.00334	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—HTR2C—type 2 diabetes mellitus	0.00081	0.00333	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GRK5—type 2 diabetes mellitus	0.000807	0.00331	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GIPR—type 2 diabetes mellitus	0.000807	0.00331	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP9—type 2 diabetes mellitus	0.000796	0.00327	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—EDNRA—type 2 diabetes mellitus	0.000788	0.00324	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AVP—type 2 diabetes mellitus	0.000784	0.00322	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GIP—type 2 diabetes mellitus	0.000782	0.00321	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—ADRA2A—type 2 diabetes mellitus	0.000771	0.00317	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GHRL—type 2 diabetes mellitus	0.000768	0.00315	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CCL2—type 2 diabetes mellitus	0.00076	0.00312	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VPS26A—type 2 diabetes mellitus	0.000759	0.00312	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CALCA—type 2 diabetes mellitus	0.000758	0.00312	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—EDN1—type 2 diabetes mellitus	0.000746	0.00306	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MC4R—type 2 diabetes mellitus	0.000738	0.00303	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GIP—type 2 diabetes mellitus	0.00071	0.00292	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GCG—type 2 diabetes mellitus	0.000702	0.00288	CbGpPWpGaD
Fosaprepitant—TACR1—G alpha (q) signalling events—PIK3R1—type 2 diabetes mellitus	0.000686	0.00282	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CASP3—type 2 diabetes mellitus	0.000673	0.00277	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR5—type 2 diabetes mellitus	0.000667	0.00274	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB3—type 2 diabetes mellitus	0.000665	0.00273	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TGFB1—type 2 diabetes mellitus	0.000656	0.00269	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—C3—type 2 diabetes mellitus	0.000651	0.00268	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—EGFR—type 2 diabetes mellitus	0.000643	0.00264	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CRHR1—type 2 diabetes mellitus	0.000642	0.00264	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—NFKB1—type 2 diabetes mellitus	0.00063	0.00259	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGT—type 2 diabetes mellitus	0.000619	0.00254	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—type 2 diabetes mellitus	0.000614	0.00252	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—TNF—type 2 diabetes mellitus	0.000612	0.00252	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—GNB3—type 2 diabetes mellitus	0.000605	0.00249	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB3—type 2 diabetes mellitus	0.000604	0.00248	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MTNR1A—type 2 diabetes mellitus	0.0006	0.00246	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—AVP—type 2 diabetes mellitus	0.000597	0.00245	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—MTNR1B—type 2 diabetes mellitus	0.000587	0.00241	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CRHR1—type 2 diabetes mellitus	0.000583	0.0024	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GLP1R—type 2 diabetes mellitus	0.000572	0.00235	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—type 2 diabetes mellitus	0.000571	0.00235	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—EDN1—type 2 diabetes mellitus	0.000568	0.00233	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CCKAR—type 2 diabetes mellitus	0.000563	0.00231	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MTNR1B—type 2 diabetes mellitus	0.000533	0.00219	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—GLP1R—type 2 diabetes mellitus	0.00052	0.00214	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GCGR—type 2 diabetes mellitus	0.000518	0.00213	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CCKAR—type 2 diabetes mellitus	0.000511	0.0021	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCL2—type 2 diabetes mellitus	0.00051	0.00209	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CCR5—type 2 diabetes mellitus	0.000508	0.00209	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—IAPP—type 2 diabetes mellitus	0.000507	0.00208	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—C3—type 2 diabetes mellitus	0.000496	0.00204	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	0.000495	0.00203	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—IL6—type 2 diabetes mellitus	0.000494	0.00203	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	0.000492	0.00202	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TNF—type 2 diabetes mellitus	0.00049	0.00201	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GIPR—type 2 diabetes mellitus	0.000477	0.00196	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GRK5—type 2 diabetes mellitus	0.000477	0.00196	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	0.000471	0.00194	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—AGT—type 2 diabetes mellitus	0.000471	0.00194	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IAPP—type 2 diabetes mellitus	0.00046	0.00189	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	0.000458	0.00188	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	0.00045	0.00185	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	0.000447	0.00184	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	0.000445	0.00183	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MC4R—type 2 diabetes mellitus	0.000436	0.00179	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	0.000436	0.00179	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	0.000434	0.00178	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	0.000429	0.00176	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	0.000428	0.00176	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000425	0.000634	CcSEcCtD
Fosaprepitant—Discomfort—Metformin—type 2 diabetes mellitus	0.000425	0.000633	CcSEcCtD
Fosaprepitant—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000425	0.000633	CcSEcCtD
Fosaprepitant—Nausea—Glipizide—type 2 diabetes mellitus	0.000424	0.000631	CcSEcCtD
Fosaprepitant—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000423	0.00063	CcSEcCtD
Fosaprepitant—Hypotension—Valsartan—type 2 diabetes mellitus	0.000423	0.00063	CcSEcCtD
Fosaprepitant—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000422	0.000628	CcSEcCtD
Fosaprepitant—Constipation—Gliclazide—type 2 diabetes mellitus	0.000421	0.000628	CcSEcCtD
Fosaprepitant—Pain—Gliclazide—type 2 diabetes mellitus	0.000421	0.000628	CcSEcCtD
Fosaprepitant—Rash—Glimepiride—type 2 diabetes mellitus	0.00042	0.000625	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—GIP—type 2 diabetes mellitus	0.00042	0.00172	CbGpPWpGaD
Fosaprepitant—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000419	0.000625	CcSEcCtD
Fosaprepitant—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000419	0.000624	CcSEcCtD
Fosaprepitant—Rash—Sitagliptin—type 2 diabetes mellitus	0.000418	0.000623	CcSEcCtD
Fosaprepitant—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000418	0.000623	CcSEcCtD
Fosaprepitant—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000418	0.000623	CcSEcCtD
Fosaprepitant—Headache—Glimepiride—type 2 diabetes mellitus	0.000417	0.000621	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.000416	0.00062	CcSEcCtD
Fosaprepitant—Cough—Irbesartan—type 2 diabetes mellitus	0.000416	0.00062	CcSEcCtD
Fosaprepitant—Headache—Sitagliptin—type 2 diabetes mellitus	0.000416	0.000619	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	0.000416	0.00171	CbGpPWpGaD
Fosaprepitant—Anaemia—Losartan—type 2 diabetes mellitus	0.000415	0.000618	CcSEcCtD
Fosaprepitant—Oedema—Metformin—type 2 diabetes mellitus	0.000412	0.000614	CcSEcCtD
Fosaprepitant—Tinnitus—Ramipril—type 2 diabetes mellitus	0.000412	0.000614	CcSEcCtD
Fosaprepitant—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000412	0.000613	CcSEcCtD
Fosaprepitant—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000411	0.000612	CcSEcCtD
Fosaprepitant—Flushing—Ramipril—type 2 diabetes mellitus	0.00041	0.000611	CcSEcCtD
Fosaprepitant—Angioedema—Losartan—type 2 diabetes mellitus	0.00041	0.000611	CcSEcCtD
Fosaprepitant—Infection—Metformin—type 2 diabetes mellitus	0.00041	0.00061	CcSEcCtD
Fosaprepitant—Insomnia—Valsartan—type 2 diabetes mellitus	0.00041	0.00061	CcSEcCtD
Fosaprepitant—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000406	0.000605	CcSEcCtD
Fosaprepitant—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000406	0.000605	CcSEcCtD
Fosaprepitant—Shock—Metformin—type 2 diabetes mellitus	0.000406	0.000604	CcSEcCtD
Fosaprepitant—Insomnia—Orlistat—type 2 diabetes mellitus	0.000405	0.000603	CcSEcCtD
Fosaprepitant—Malaise—Losartan—type 2 diabetes mellitus	0.000405	0.000603	CcSEcCtD
Fosaprepitant—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000405	0.000603	CcSEcCtD
Fosaprepitant—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000404	0.000602	CcSEcCtD
Fosaprepitant—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000404	0.000602	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	0.000404	0.00166	CbGpPWpGaD
Fosaprepitant—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000404	0.000601	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000403	0.000601	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000403	0.0006	CcSEcCtD
Fosaprepitant—Somnolence—Valsartan—type 2 diabetes mellitus	0.000403	0.0006	CcSEcCtD
Fosaprepitant—Syncope—Losartan—type 2 diabetes mellitus	0.000402	0.0006	CcSEcCtD
Fosaprepitant—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000401	0.000598	CcSEcCtD
Fosaprepitant—Skin disorder—Metformin—type 2 diabetes mellitus	0.000401	0.000597	CcSEcCtD
Fosaprepitant—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000399	0.000595	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—LEPR—type 2 diabetes mellitus	0.000399	0.00164	CbGpPWpGaD
Fosaprepitant—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000399	0.000594	CcSEcCtD
Fosaprepitant—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000399	0.000594	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000398	0.000593	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—type 2 diabetes mellitus	0.000398	0.00163	CbGpPWpGaD
Fosaprepitant—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000397	0.000592	CcSEcCtD
Fosaprepitant—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000397	0.000591	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—GCG—type 2 diabetes mellitus	0.000397	0.00163	CbGpPWpGaD
Fosaprepitant—Palpitations—Losartan—type 2 diabetes mellitus	0.000397	0.000591	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	0.000396	0.00163	CbGpPWpGaD
Fosaprepitant—Nausea—Glimepiride—type 2 diabetes mellitus	0.000395	0.000589	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6—type 2 diabetes mellitus	0.000395	0.00162	CbGpPWpGaD
Fosaprepitant—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000394	0.000588	CcSEcCtD
Fosaprepitant—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000394	0.000587	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—GHRL—type 2 diabetes mellitus	0.000394	0.00162	CbGpPWpGaD
Fosaprepitant—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000394	0.000587	CcSEcCtD
Fosaprepitant—Asthenia—Glyburide—type 2 diabetes mellitus	0.000394	0.000587	CcSEcCtD
Fosaprepitant—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000394	0.000586	CcSEcCtD
Fosaprepitant—Cough—Losartan—type 2 diabetes mellitus	0.000392	0.000583	CcSEcCtD
Fosaprepitant—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000392	0.000583	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000391	0.000582	CcSEcCtD
Fosaprepitant—Fatigue—Valsartan—type 2 diabetes mellitus	0.00039	0.000582	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	0.00039	0.0016	CbGpPWpGaD
Fosaprepitant—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.00039	0.00058	CcSEcCtD
Fosaprepitant—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.00039	0.00058	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CALCA—type 2 diabetes mellitus	0.000389	0.0016	CbGpPWpGaD
Fosaprepitant—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000389	0.00058	CcSEcCtD
Fosaprepitant—Oedema—Irbesartan—type 2 diabetes mellitus	0.000389	0.00058	CcSEcCtD
Fosaprepitant—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000389	0.000579	CcSEcCtD
Fosaprepitant—Pruritus—Glyburide—type 2 diabetes mellitus	0.000388	0.000579	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CCL2—type 2 diabetes mellitus	0.000388	0.00159	CbGpPWpGaD
Fosaprepitant—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000387	0.000577	CcSEcCtD
Fosaprepitant—Constipation—Valsartan—type 2 diabetes mellitus	0.000387	0.000577	CcSEcCtD
Fosaprepitant—Infection—Irbesartan—type 2 diabetes mellitus	0.000387	0.000576	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000386	0.000576	CcSEcCtD
Fosaprepitant—Fatigue—Orlistat—type 2 diabetes mellitus	0.000386	0.000575	CcSEcCtD
Fosaprepitant—Hypotension—Metformin—type 2 diabetes mellitus	0.000385	0.000574	CcSEcCtD
Fosaprepitant—Erythema—Ramipril—type 2 diabetes mellitus	0.000385	0.000573	CcSEcCtD
Fosaprepitant—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000385	0.000573	CcSEcCtD
Fosaprepitant—Shock—Irbesartan—type 2 diabetes mellitus	0.000383	0.00057	CcSEcCtD
Fosaprepitant—Pain—Orlistat—type 2 diabetes mellitus	0.000383	0.00057	CcSEcCtD
Fosaprepitant—Chest pain—Losartan—type 2 diabetes mellitus	0.000382	0.000569	CcSEcCtD
Fosaprepitant—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000382	0.000569	CcSEcCtD
Fosaprepitant—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000382	0.000569	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	0.000381	0.00157	CbGpPWpGaD
Fosaprepitant—Anxiety—Losartan—type 2 diabetes mellitus	0.000381	0.000567	CcSEcCtD
Fosaprepitant—Rash—Bromocriptine—type 2 diabetes mellitus	0.000379	0.000564	CcSEcCtD
Fosaprepitant—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000378	0.000563	CcSEcCtD
Fosaprepitant—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000378	0.000563	CcSEcCtD
Fosaprepitant—Discomfort—Losartan—type 2 diabetes mellitus	0.000377	0.000562	CcSEcCtD
Fosaprepitant—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000377	0.000561	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000376	0.00056	CcSEcCtD
Fosaprepitant—Headache—Bromocriptine—type 2 diabetes mellitus	0.000376	0.00056	CcSEcCtD
Fosaprepitant—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000376	0.000559	CcSEcCtD
Fosaprepitant—Dry mouth—Losartan—type 2 diabetes mellitus	0.000374	0.000557	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TLE4—type 2 diabetes mellitus	0.000371	0.00152	CbGpPWpGaD
Fosaprepitant—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.00037	0.000552	CcSEcCtD
Fosaprepitant—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.00037	0.000551	CcSEcCtD
Fosaprepitant—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000369	0.000549	CcSEcCtD
Fosaprepitant—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000368	0.000548	CcSEcCtD
Fosaprepitant—Somnolence—Metformin—type 2 diabetes mellitus	0.000367	0.000546	CcSEcCtD
Fosaprepitant—Oedema—Losartan—type 2 diabetes mellitus	0.000366	0.000546	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000366	0.000546	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000366	0.000545	CcSEcCtD
Fosaprepitant—Infection—Losartan—type 2 diabetes mellitus	0.000364	0.000542	CcSEcCtD
Fosaprepitant—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000364	0.000542	CcSEcCtD
Fosaprepitant—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000363	0.000541	CcSEcCtD
Fosaprepitant—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000363	0.000541	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—GCG—type 2 diabetes mellitus	0.00036	0.00148	CbGpPWpGaD
Fosaprepitant—Shock—Losartan—type 2 diabetes mellitus	0.00036	0.000537	CcSEcCtD
Fosaprepitant—Urticaria—Valsartan—type 2 diabetes mellitus	0.00036	0.000536	CcSEcCtD
Fosaprepitant—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000359	0.000535	CcSEcCtD
Fosaprepitant—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000358	0.000534	CcSEcCtD
Fosaprepitant—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000358	0.000533	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000357	0.000532	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ADRB3—type 2 diabetes mellitus	0.000357	0.00147	CbGpPWpGaD
Fosaprepitant—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000357	0.000531	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000356	0.00053	CcSEcCtD
Fosaprepitant—Fatigue—Metformin—type 2 diabetes mellitus	0.000355	0.00053	CcSEcCtD
Fosaprepitant—Urticaria—Orlistat—type 2 diabetes mellitus	0.000355	0.00053	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	0.000354	0.00146	CbGpPWpGaD
Fosaprepitant—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000354	0.000527	CcSEcCtD
Fosaprepitant—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000354	0.000527	CcSEcCtD
Fosaprepitant—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000354	0.000527	CcSEcCtD
Fosaprepitant—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000354	0.000527	CcSEcCtD
Fosaprepitant—Constipation—Metformin—type 2 diabetes mellitus	0.000353	0.000525	CcSEcCtD
Fosaprepitant—Angioedema—Ramipril—type 2 diabetes mellitus	0.000352	0.000524	CcSEcCtD
Fosaprepitant—Vomiting—Glyburide—type 2 diabetes mellitus	0.000349	0.00052	CcSEcCtD
Fosaprepitant—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000349	0.000519	CcSEcCtD
Fosaprepitant—Malaise—Ramipril—type 2 diabetes mellitus	0.000347	0.000517	CcSEcCtD
Fosaprepitant—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000347	0.000517	CcSEcCtD
Fosaprepitant—Rash—Glyburide—type 2 diabetes mellitus	0.000346	0.000516	CcSEcCtD
Fosaprepitant—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000346	0.000515	CcSEcCtD
Fosaprepitant—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000346	0.000515	CcSEcCtD
Fosaprepitant—Syncope—Ramipril—type 2 diabetes mellitus	0.000345	0.000514	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CRHR1—type 2 diabetes mellitus	0.000345	0.00142	CbGpPWpGaD
Fosaprepitant—Headache—Glyburide—type 2 diabetes mellitus	0.000344	0.000512	CcSEcCtD
Fosaprepitant—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000343	0.00051	CcSEcCtD
Fosaprepitant—Hypotension—Losartan—type 2 diabetes mellitus	0.000342	0.00051	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	0.000342	0.0014	CbGpPWpGaD
Fosaprepitant—Palpitations—Ramipril—type 2 diabetes mellitus	0.00034	0.000507	CcSEcCtD
Fosaprepitant—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.00034	0.000506	CcSEcCtD
Fosaprepitant—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000338	0.000504	CcSEcCtD
Fosaprepitant—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000338	0.000504	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—AVP—type 2 diabetes mellitus	0.000337	0.00139	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000337	0.000502	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000337	0.000502	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000336	0.000501	CcSEcCtD
Fosaprepitant—Cough—Ramipril—type 2 diabetes mellitus	0.000336	0.0005	CcSEcCtD
Fosaprepitant—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000335	0.0005	CcSEcCtD
Fosaprepitant—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000334	0.000497	CcSEcCtD
Fosaprepitant—Constipation—Irbesartan—type 2 diabetes mellitus	0.000333	0.000496	CcSEcCtD
Fosaprepitant—Pain—Irbesartan—type 2 diabetes mellitus	0.000333	0.000496	CcSEcCtD
Fosaprepitant—Insomnia—Losartan—type 2 diabetes mellitus	0.000331	0.000493	CcSEcCtD
Fosaprepitant—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.00033	0.000491	CcSEcCtD
Fosaprepitant—Urticaria—Metformin—type 2 diabetes mellitus	0.000328	0.000488	CcSEcCtD
Fosaprepitant—Chest pain—Ramipril—type 2 diabetes mellitus	0.000328	0.000488	CcSEcCtD
Fosaprepitant—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000326	0.000486	CcSEcCtD
Fosaprepitant—Anxiety—Ramipril—type 2 diabetes mellitus	0.000326	0.000486	CcSEcCtD
Fosaprepitant—Nausea—Glyburide—type 2 diabetes mellitus	0.000326	0.000486	CcSEcCtD
Fosaprepitant—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000326	0.000486	CcSEcCtD
Fosaprepitant—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000326	0.000486	CcSEcCtD
Fosaprepitant—Somnolence—Losartan—type 2 diabetes mellitus	0.000326	0.000485	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000325	0.000485	CcSEcCtD
Fosaprepitant—Asthenia—Valsartan—type 2 diabetes mellitus	0.000325	0.000484	CcSEcCtD
Fosaprepitant—Discomfort—Ramipril—type 2 diabetes mellitus	0.000324	0.000482	CcSEcCtD
Fosaprepitant—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000322	0.00048	CcSEcCtD
Fosaprepitant—Asthenia—Orlistat—type 2 diabetes mellitus	0.000321	0.000478	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	0.000321	0.00132	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000321	0.000478	CcSEcCtD
Fosaprepitant—Pruritus—Valsartan—type 2 diabetes mellitus	0.00032	0.000477	CcSEcCtD
Fosaprepitant—Dry mouth—Ramipril—type 2 diabetes mellitus	0.00032	0.000477	CcSEcCtD
Fosaprepitant—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000318	0.000474	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000318	0.000474	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	0.000318	0.00131	CbGpPWpGaD
Fosaprepitant—Pruritus—Orlistat—type 2 diabetes mellitus	0.000317	0.000472	CcSEcCtD
Fosaprepitant—Fatigue—Losartan—type 2 diabetes mellitus	0.000316	0.00047	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	0.000315	0.00129	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SPRY2—type 2 diabetes mellitus	0.000315	0.00129	CbGpPWpGaD
Fosaprepitant—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000314	0.000468	CcSEcCtD
Fosaprepitant—Oedema—Ramipril—type 2 diabetes mellitus	0.000314	0.000468	CcSEcCtD
Fosaprepitant—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000313	0.000467	CcSEcCtD
Fosaprepitant—Constipation—Losartan—type 2 diabetes mellitus	0.000313	0.000467	CcSEcCtD
Fosaprepitant—Pain—Losartan—type 2 diabetes mellitus	0.000313	0.000467	CcSEcCtD
Fosaprepitant—Rash—Gliclazide—type 2 diabetes mellitus	0.000311	0.000463	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—GNB3—type 2 diabetes mellitus	0.000311	0.00128	CbGpPWpGaD
Fosaprepitant—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.00031	0.000463	CcSEcCtD
Fosaprepitant—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.00031	0.000462	CcSEcCtD
Fosaprepitant—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000309	0.000461	CcSEcCtD
Fosaprepitant—Shock—Ramipril—type 2 diabetes mellitus	0.000309	0.00046	CcSEcCtD
Fosaprepitant—Headache—Gliclazide—type 2 diabetes mellitus	0.000309	0.00046	CcSEcCtD
Fosaprepitant—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000308	0.000459	CcSEcCtD
Fosaprepitant—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000308	0.000458	CcSEcCtD
Fosaprepitant—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000308	0.000458	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RBP4—type 2 diabetes mellitus	0.000307	0.00126	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GLP1R—type 2 diabetes mellitus	0.000307	0.00126	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AVP—type 2 diabetes mellitus	0.000306	0.00126	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—MMP3—type 2 diabetes mellitus	0.000306	0.00126	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000306	0.000456	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—type 2 diabetes mellitus	0.000306	0.00126	CbGpPWpGaD
Fosaprepitant—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000305	0.000454	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	0.000305	0.00125	CbGpPWpGaD
Fosaprepitant—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000304	0.000452	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CCKAR—type 2 diabetes mellitus	0.000302	0.00124	CbGpPWpGaD
Fosaprepitant—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000302	0.00045	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000299	0.000446	CcSEcCtD
Fosaprepitant—Dizziness—Valsartan—type 2 diabetes mellitus	0.000299	0.000446	CcSEcCtD
Fosaprepitant—Dizziness—Orlistat—type 2 diabetes mellitus	0.000296	0.000441	CcSEcCtD
Fosaprepitant—Asthenia—Metformin—type 2 diabetes mellitus	0.000296	0.000441	CcSEcCtD
Fosaprepitant—Hypotension—Ramipril—type 2 diabetes mellitus	0.000293	0.000437	CcSEcCtD
Fosaprepitant—Nausea—Gliclazide—type 2 diabetes mellitus	0.000293	0.000436	CcSEcCtD
Fosaprepitant—Pruritus—Metformin—type 2 diabetes mellitus	0.000292	0.000435	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—EDN1—type 2 diabetes mellitus	0.000291	0.0012	CbGpPWpGaD
Fosaprepitant—Urticaria—Losartan—type 2 diabetes mellitus	0.000291	0.000433	CcSEcCtD
Fosaprepitant—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000289	0.000431	CcSEcCtD
Fosaprepitant—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000289	0.000431	CcSEcCtD
Fosaprepitant—Vomiting—Valsartan—type 2 diabetes mellitus	0.000288	0.000429	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	0.000287	0.00118	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000287	0.000427	CcSEcCtD
Fosaprepitant—Rash—Valsartan—type 2 diabetes mellitus	0.000285	0.000425	CcSEcCtD
Fosaprepitant—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000285	0.000425	CcSEcCtD
Fosaprepitant—Vomiting—Orlistat—type 2 diabetes mellitus	0.000284	0.000424	CcSEcCtD
Fosaprepitant—Insomnia—Ramipril—type 2 diabetes mellitus	0.000284	0.000423	CcSEcCtD
Fosaprepitant—Headache—Valsartan—type 2 diabetes mellitus	0.000284	0.000423	CcSEcCtD
Fosaprepitant—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000282	0.00042	CcSEcCtD
Fosaprepitant—Rash—Orlistat—type 2 diabetes mellitus	0.000282	0.00042	CcSEcCtD
Fosaprepitant—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000282	0.00042	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—C3—type 2 diabetes mellitus	0.00028	0.00115	CbGpPWpGaD
Fosaprepitant—Headache—Orlistat—type 2 diabetes mellitus	0.00028	0.000418	CcSEcCtD
Fosaprepitant—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.00028	0.000417	CcSEcCtD
Fosaprepitant—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000279	0.000416	CcSEcCtD
Fosaprepitant—Somnolence—Ramipril—type 2 diabetes mellitus	0.000279	0.000416	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	0.000277	0.00114	CbGpPWpGaD
Fosaprepitant—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000276	0.000412	CcSEcCtD
Fosaprepitant—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000275	0.00041	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	0.000274	0.00112	CbGpPWpGaD
Fosaprepitant—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000273	0.000407	CcSEcCtD
Fosaprepitant—Dizziness—Metformin—type 2 diabetes mellitus	0.000273	0.000406	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—IAPP—type 2 diabetes mellitus	0.000272	0.00112	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000271	0.000404	CcSEcCtD
Fosaprepitant—Fatigue—Ramipril—type 2 diabetes mellitus	0.000271	0.000403	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—INSR—type 2 diabetes mellitus	0.00027	0.00111	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.00027	0.000402	CcSEcCtD
Fosaprepitant—Nausea—Valsartan—type 2 diabetes mellitus	0.000269	0.000401	CcSEcCtD
Fosaprepitant—Constipation—Ramipril—type 2 diabetes mellitus	0.000269	0.0004	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	0.000266	0.00109	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000266	0.000397	CcSEcCtD
Fosaprepitant—Nausea—Orlistat—type 2 diabetes mellitus	0.000266	0.000396	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	0.000266	0.00109	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	0.000265	0.00109	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	0.000264	0.00108	CbGpPWpGaD
Fosaprepitant—Asthenia—Losartan—type 2 diabetes mellitus	0.000263	0.000391	CcSEcCtD
Fosaprepitant—Vomiting—Metformin—type 2 diabetes mellitus	0.000262	0.000391	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	0.000261	0.00107	CbGpPWpGaD
Fosaprepitant—Rash—Metformin—type 2 diabetes mellitus	0.00026	0.000387	CcSEcCtD
Fosaprepitant—Dermatitis—Metformin—type 2 diabetes mellitus	0.00026	0.000387	CcSEcCtD
Fosaprepitant—Pruritus—Losartan—type 2 diabetes mellitus	0.000259	0.000386	CcSEcCtD
Fosaprepitant—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000259	0.000386	CcSEcCtD
Fosaprepitant—Headache—Metformin—type 2 diabetes mellitus	0.000258	0.000385	CcSEcCtD
Fosaprepitant—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000257	0.000383	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000257	0.000383	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—C3—type 2 diabetes mellitus	0.000255	0.00105	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	0.000253	0.00104	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000251	0.000373	CcSEcCtD
Fosaprepitant—Urticaria—Ramipril—type 2 diabetes mellitus	0.000249	0.000372	CcSEcCtD
Fosaprepitant—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.000248	0.00037	CcSEcCtD
Fosaprepitant—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000248	0.00037	CcSEcCtD
Fosaprepitant—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000247	0.000369	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	0.000246	0.00101	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	0.000245	0.00101	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	0.000245	0.00101	CbGpPWpGaD
Fosaprepitant—Rash—Irbesartan—type 2 diabetes mellitus	0.000245	0.000366	CcSEcCtD
Fosaprepitant—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000245	0.000365	CcSEcCtD
Fosaprepitant—Nausea—Metformin—type 2 diabetes mellitus	0.000245	0.000365	CcSEcCtD
Fosaprepitant—Headache—Irbesartan—type 2 diabetes mellitus	0.000244	0.000363	CcSEcCtD
Fosaprepitant—Dizziness—Losartan—type 2 diabetes mellitus	0.000242	0.000361	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—AGT—type 2 diabetes mellitus	0.000242	0.000994	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	0.000239	0.000981	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	0.000238	0.000977	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CYBA—type 2 diabetes mellitus	0.000238	0.000977	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	0.000234	0.00096	CbGpPWpGaD
Fosaprepitant—Vomiting—Losartan—type 2 diabetes mellitus	0.000233	0.000347	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—PLAT—type 2 diabetes mellitus	0.000233	0.000956	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GHRL—type 2 diabetes mellitus	0.000233	0.000956	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000231	0.000345	CcSEcCtD
Fosaprepitant—Nausea—Irbesartan—type 2 diabetes mellitus	0.000231	0.000344	CcSEcCtD
Fosaprepitant—Rash—Losartan—type 2 diabetes mellitus	0.000231	0.000344	CcSEcCtD
Fosaprepitant—Dermatitis—Losartan—type 2 diabetes mellitus	0.000231	0.000344	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CALCA—type 2 diabetes mellitus	0.00023	0.000944	CbGpPWpGaD
Fosaprepitant—Headache—Losartan—type 2 diabetes mellitus	0.000229	0.000342	CcSEcCtD
Fosaprepitant—Asthenia—Ramipril—type 2 diabetes mellitus	0.000225	0.000336	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	0.000224	0.000918	CbGpPWpGaD
Fosaprepitant—Pruritus—Ramipril—type 2 diabetes mellitus	0.000222	0.000331	CcSEcCtD
Fosaprepitant—Nausea—Losartan—type 2 diabetes mellitus	0.000218	0.000324	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	0.000217	0.000889	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	0.000216	0.000885	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000215	0.00032	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—GCG—type 2 diabetes mellitus	0.000213	0.000874	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	0.000213	0.000874	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	0.000209	0.00086	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	0.000209	0.000858	CbGpPWpGaD
Fosaprepitant—Dizziness—Ramipril—type 2 diabetes mellitus	0.000208	0.000309	CcSEcCtD
Fosaprepitant—Vomiting—Ramipril—type 2 diabetes mellitus	0.0002	0.000297	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	0.000199	0.000818	CbGpPWpGaD
Fosaprepitant—Rash—Ramipril—type 2 diabetes mellitus	0.000198	0.000295	CcSEcCtD
Fosaprepitant—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000198	0.000295	CcSEcCtD
Fosaprepitant—Headache—Ramipril—type 2 diabetes mellitus	0.000197	0.000293	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	0.000196	0.000804	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	0.000196	0.000803	CbGpPWpGaD
Fosaprepitant—Nausea—Ramipril—type 2 diabetes mellitus	0.000187	0.000278	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	0.000185	0.000761	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—GNB3—type 2 diabetes mellitus	0.000183	0.000754	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AVP—type 2 diabetes mellitus	0.000181	0.000744	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP3—type 2 diabetes mellitus	0.000181	0.000744	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IGF2—type 2 diabetes mellitus	0.00018	0.00074	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	0.000179	0.000737	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	0.000178	0.000729	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOB—type 2 diabetes mellitus	0.000175	0.000719	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	0.000174	0.000716	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EDN1—type 2 diabetes mellitus	0.000172	0.000707	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LPL—type 2 diabetes mellitus	0.000167	0.000686	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	0.000164	0.000672	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	0.000157	0.000644	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCR5—type 2 diabetes mellitus	0.000154	0.000632	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—C3—type 2 diabetes mellitus	0.00015	0.000618	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	0.000143	0.000589	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IRS2—type 2 diabetes mellitus	0.000143	0.000588	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AGT—type 2 diabetes mellitus	0.000143	0.000587	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CALM1—type 2 diabetes mellitus	0.00014	0.000577	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LEP—type 2 diabetes mellitus	0.00014	0.000575	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOE—type 2 diabetes mellitus	0.00014	0.000575	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—APOA1—type 2 diabetes mellitus	0.000138	0.000569	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	0.000132	0.000542	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IRS1—type 2 diabetes mellitus	0.000125	0.000513	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—INS—type 2 diabetes mellitus	0.00012	0.000491	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CCL2—type 2 diabetes mellitus	0.000118	0.000483	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IGF1—type 2 diabetes mellitus	0.000116	0.000475	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT2—type 2 diabetes mellitus	0.000116	0.000475	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	0.000115	0.000473	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	0.00011	0.000451	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOS3—type 2 diabetes mellitus	0.000105	0.000431	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	0.000105	0.000431	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—RELA—type 2 diabetes mellitus	9.87e-05	0.000406	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	8.99e-05	0.000369	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.9e-05	0.000366	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6—type 2 diabetes mellitus	8.85e-05	0.000363	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.42e-05	0.000346	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.33e-05	0.000342	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.16e-05	0.000335	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SRC—type 2 diabetes mellitus	7.76e-05	0.000319	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.56e-05	0.00031	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.94e-05	0.000285	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.8e-05	0.000279	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.23e-05	0.000215	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.82e-05	0.000198	CbGpPWpGaD
